The USFDA has awarded a Fast Track Designation to Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD)’s pixantrone for relapsed indolent non-Hodgkin's lymphoma (NHL).
Pixantrone is a novel anthracenedione, being investigated by CTI for the potential treatment of relapsed or refractory indolent non-Hodgkin's lymphoma (NHL) that has shown potential (from phase I and phase III studies) in the treatment of relapsed or refractory indolent NHL.
Relapsed or refractory indolent NHL is a serious and life threatening condition and is generally considered incurable.
According to James A. Bianco, M.D., President and CEO of CTI:
"With fast track designation already granted for pixantrone in aggressive NHL, this designation for indolent NHL is an important step in the development of this product and may help us bring this potentially life-saving drug to patients more quickly."Find more details from the full report.
Comment Preview